Supplement

You have full text access to this OnlineOpen article

Predicting the effect of successful human papillomavirus vaccination on existing cervical cancer prevention programs in the United States†‡§‖††

  1. Philip E. Castle PhD, MPH1,
  2. Diane Solomon MD2,‡‡,*,
  3. Debbie Saslow PhD3,
  4. Mark Schiffman MD, MPH1

Article first published online: 3 NOV 2008

DOI: 10.1002/cncr.23762

Issue

Cancer

Cancer

Supplement: Assessing the Burden of HPV-Associated Cancers in the United States

Volume 113, Issue Supplement 10, pages 3031–3035, 15 November 2008

Additional Information

How to Cite

Castle, P. E., Solomon, D., Saslow, D. and Schiffman, M. (2008), Predicting the effect of successful human papillomavirus vaccination on existing cervical cancer prevention programs in the United States. Cancer, 113: 3031–3035. doi: 10.1002/cncr.23762

Author Information

  1. 1

    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, Maryland

  2. 2

    Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, Maryland

  3. 3

    American Cancer Society, Atlanta, Georgia.

  1. ‡‡

    Fax: (301) 480-9939.

*Division of Cancer Prevention, National Cancer Institute, EPN Room 2130; 6130 Executive Boulevard, Rockville, MD 20852;

  1. †

    A National Cancer Institute (NCI)-sponsored clinical trial of the GlaxoSmithKline (GSK) human papillomavirus vaccine receives vaccine from the manufacturer (GSK) at no cost. GSK also provides support for aspects of the trial associated with regulatory submission needs to the US Federal Drug Administration.

  2. ‡

    The following companies have provided research support in the form of equipment or supplies at reduced or no cost for NCI-sponsored trials: Cytyc Corporation, Digene Corporation, GSK, TriPath, and Roche Molecular Systems. The work was supported (in part) by the Intramural Research Program of the NCI, National Institutes of Health (NIH).

  3. §

    The authors have no personal financial conflict of interest to report. The financial activities of the NCI authors are monitored by the NCI Ethics Office.

  4. The views and opinions within are those of the authors alone and do not necessarily represent the opinions of the NCI, the NIH, the Department of Health and Human Services of the US government, or any professional or clinical society.

  5. ‖

    The opinions or views expressed in this supplement are those of the authors and do not necessarily reflect the opinions or recommendations of the journal editors, the American Cancer Society, Wiley-Blackwell, or the Centers for Disease Control and Prevention.

  6. ††

    This is a US government work and, as such, is in the public domain in the United States of America.

Publication History

  1. Issue published online: 3 NOV 2008
  2. Article first published online: 3 NOV 2008
  3. Manuscript Accepted: 28 MAY 2008
  4. Manuscript Received: 14 APR 2008

Funded by

  • Cooperative Agreement. Grant Number: U50 DP424071-04
  • Centers for Disease Control and Prevention (CDC)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (77K)

REFERENCES

  • 1
    Munoz N,Bosch FX,Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004; 20:111: 278–285.
    Direct Link:
  • 2
    Dunne EF,Datta SD,Markowitz L. A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the United States. Cancer. 2008; 113( 10 suppl): 2995–3003.
    Direct Link:
  • 3
    Hildesheim A,Herrero R,Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA. 2007; 298: 743–753.
  • 4
    FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007; 356: 1915–1927.
  • 5
    Garland SM,Hernandez-Avila M,Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 356: 1928–1943.
  • 6
    Saslow D,Castle PE,Cox JT, et al. American Cancer Society guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin. 2007; 57: 7–28.
    Direct Link:
  • 7
    Markowitz LE,Dunne EF,Saraiya M,Lawson HW,Chesson H,Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007; 56: 1–24.
  • 8
    Schiffman M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer. 2007; 111: 145–153.
    Direct Link:
  • 9
    Kovacic MB,Castle PE,Herrero R, et al. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res. 2006; 66: 10112–10119.
  • 10
    Paavonen J,Jenkins D,Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007; 369: 2161–2170.
  • 11
    Davey DD,Neal MH,Wilbur DC,Colgan TJ,Styer PE,Mody DR. Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology. Arch Pathol Lab Med. 2004; 128: 1224–129.
  • 12
    Khan MJ,Castle PE,Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005; 20:97: 1072–109.
  • 13
    Plummer M,Schiffman M,Castle PE,Maucort-Boulch D,Wheeler CM. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis. 2007; 195: 1582–159.
  • 14
    Rodriguez AC,Schiffman M,Herrero R, et al; Proyecto Epidemiologico Guanacastle Group. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst. 2008: 100: 513–517.
  • 15
    Stoler MH,Castle PE,Solomon D,Schiffman M. The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays. Am J Clin Pathol. 2007; 127: 1–3.
  • 16
    Jeronimo J,Massad LS,Schiffman M. Visual appearance of the uterine cervix: correlation with human papillomavirus detection and type. Am J Obstet Gynecol. 2007; 197: 47–48.
  • 17
    Lorincz AT,Reid R,Jenson AB,Greenberg MD,Lancaster W,Kurman RJ. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol. 1992; 79: 328–337.
  • 18
    Smith JS,Lindsay L,Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007; 121: 621–632.
    Direct Link:
  • 19
    Castle PE,Stoler MH,Solomon D,Schiffman M. The relationship of community biopsy-diagnosed cervical intraepithelial neoplasia grade 2 to the quality control pathology-reviewed diagnoses: an ALTS report. Am J Clin Pathol. 2007; 127: 805–815.
  • 20
    Kyrgiou M,Koliopoulos G,Martin-Hirsch P,Arbyn M,Prendiville W,Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet. 2006; 367: 489–498.
  • 21
    Saraiya M,Goodman MT,Datta SD,Chen VW,Wingo PA. Cancer registries and monitoring the impact of prophylactic human papillomavirus vaccines: the potential role [commentary]. Cancer. 2008; 113( 10 suppl): 3047–3057.
    Direct Link:
  • 22
    Goldhaber-Fiebert JD,Stout NK,Salomon JA,Kuntz KM,Goldie SJ. Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst. 2008; 100: 308–320.
  • 23
    Saslow D,Runowicz CD,Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002; 52: 342–362.
    Direct Link:
  • 24
    Wright TCJr,Massad LS,Dunton CJ,Spitzer M,Wilkinson EJ,Solomon D. 2006 Consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol. 2007; 197: 346–355.
  • 25
    Davey E,d'Assuncao J,Irwig L, et al. Accuracy of reading liquid based cytology slides using the ThinPrep Imager compared with conventional cytology: prospective study. BMJ. 2007; 335: 31–31.
  • 26
    Wentzensen N,von Knebel DM. Biomarkers in cervical cancer screening. Dis Markers. 2007; 23: 315–330.
  • 27
    Naucler P,Ryd W,Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007; 357: 1589–1597.
  • 28
    Mayrand MH,Duarte-Franco E,Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007; 357: 1579–1588.
  • 29
    Ronco G,Giorgi-Rossi P,Carozzi F, et al. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment fora randomised controlled trial. Lancet Oncol. 2006; 7: 547–555.
  • 30
    Bulkmans NW,Berkhof J,Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet. 2007; 370: 1764–1772.
  • 31
    Ronco G,Segnan N,Giorgi-Rossi P, et al. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst. 2006; 98: 765–774.
View Full Article (HTML) Get PDF (77K)